<sup>125</sup>I标记重组人血小板生成素大鼠静脉注射后药动学参数

钱隽; 朱建华; 李端; 胡欢

doi:null

您当前的位置：

首页 >

文章列表页 >

¹²⁵I标记重组人血小板生成素大鼠静脉注射后药动学参数

更新时间：2021-03-12

- ¹²⁵I标记重组人血小板生成素大鼠静脉注射后药动学参数
- Pharmacokinetics of ¹²⁵I-recombinant human thrombopoietin in rats after i.v.
- 核技术 2005年第1期
- 作者机构：
  
  1. 复旦大学药学院放射药学教研室
  2. 复旦大学药学院药理学教研室
  3. 复旦大学药学院放射药学教研室,上海,200032
- 作者简介：
- 基金信息：
- DOI：
  中图分类号： R96
- 纸质出版日期：2005-01-01
- 稿件说明：
移动端阅览
[1]钱隽,朱建华,李端,胡欢.~(125)I标记重组人血小板生成素大鼠静脉注射后药动学参数[J].核技术,2005(01):54-56.

QIAN Jun1 ZHU Jianhua1 LI Duan2 HU Huan1 1. Pharmacokinetics of ¹²⁵I-recombinant human thrombopoietin in rats after i.v.[J]. Nuclear techniques, 2005, (1): 54-56.
[1]钱隽,朱建华,李端,胡欢.~(125)I标记重组人血小板生成素大鼠静脉注射后药动学参数[J].核技术,2005(01):54-56. DOI：

QIAN Jun1 ZHU Jianhua1 LI Duan2 HU Huan1 1. Pharmacokinetics of ¹²⁵I-recombinant human thrombopoietin in rats after i.v.[J]. Nuclear techniques, 2005, (1): 54-56. DOI：

摘要

本文目的是建立125I标记重组人血小板生成素（125I-rhTPO）的分析方法并研究大鼠单剂量静脉注射125I-rhTPO后的药动学特性。以Iodogen法制备I-rhTPO

HPLC法及SDS-PAGE法鉴定并测定放化纯度。125大鼠按2μg·kg-1剂量经尾静脉给药

于不同时相取血测放射性计数

并计算相应的血药浓度及药动学参数。制备的I-rhTPO符合药动学研究要求

标记前后化合物所在电泳位置一致

放化纯度>98%

4℃100h后125放化纯度仍大于95%。尾静脉注射2μg·kg-1

在大鼠体内可以二室模型拟合血药浓度的动态变化

T1/2（α）为（1.32±0.35）h

T1/2（为（24.55±1.07）h

AUC0β）→t为（134.26±22.99）ng·h·mL-1。Iodogen法制备125I-rhTPO

经SDS-PAGE检验

标记后的I-rhTPO与rhTPO的纯度、分子量相当

且I-rhTPO在体外稳定性较好。尾125125静脉注射2μg·kg-1

在大鼠体内可以二室模型拟合

半衰期约为25h。

Abstract

Purpose of this work is to establish the analytic method and investigate the pharmacokinetics of 125I-rhTPO in rats receiving single injection of vein. 125I-rhTPO was prepared with Iodogen method. The radiochemical purity of 125I-rhTPO was determined both by HPLC and SDS- PAGE. In the test

125I-rhTPO was injected via caudal vein at the dose of 2 μg·kg-1 in rats. Blood samples were collected at different time after i.v.

then the drug concentration was determined according to the radioactivity and the pharmacokinetic parameters were calculated. It is shown that radiochemical purity of 125I-rhTPO was above 98%

and the pharmacokinetics of 125I-rhTPO following i.v. with 2 μg·kg-1 in rats was fit to two-compartment model. The T1/2( was (1.32±0.35) h

T1/2 α) ( ) β was (24.55±1.07) h and AUC0 →t was (134.26±22.99) ng·h·mL-1. 125I-rhTPO prepared with Iodogen method was accordant with original rhTPO at purity and molecular weight by SDS PAGE test. The stability of 125I-rhTPO was good in vitro. Half -lives were about 25 h.

关键词

Keywords

references

浏览量

102

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

Iodogen法¹²⁵I标记单克隆抗体10D9

125I标记重组人血小板生成素大鼠静脉注射后药动学参数

Pharmacokinetics of 125I-recombinant human thrombopoietin in rats after i.v.

DOI：

摘要

Abstract

关键词

Keywords

references

¹²⁵I标记重组人血小板生成素大鼠静脉注射后药动学参数

Pharmacokinetics of ¹²⁵I-recombinant human thrombopoietin in rats after i.v.